D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of D-0316 in
Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has
Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
and whose Tumours are Epidermal Growth Factor Receptor Mutation and T790M Mutation Positive